Skip to content
Nonprofiteer
← GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC

Form 990 for tax year 2024

Filed by GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC.

Totals

Total revenue
$63,732,557
Total expenses
$61,508,783
Contributions and grants received
$52,737,212
Grants paid
$359,938
Program service revenue
$0
Investment income
$9,675,203
Other revenue
$1,320,142
Total assets, end of year
$204,316,428
Total liabilities, end of year
$28,006,599
Net assets or fund balances, end of year
$176,309,829
Program services expenses (Part IX)
$54,417,744
Management and general expenses
$5,733,341
Fundraising expenses
$1,357,698
Program service expenses (Part III)
$54,417,744

Program services were 88.5% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1e · Government grants (contributions)

    $35,728,256

  • 1f · All other contributions, gifts and grants

    $17,008,956

  • 2f · All other program service revenue

    total $0 · related or exempt $0 · unrelated business $0 · excluded $0

  • 3 · Investment income

    total $6,018,797 · related or exempt $0 · unrelated business $0 · excluded $6,018,797

  • 5 · Royalties

    total $387,789 · related or exempt $0 · unrelated business $0 · excluded $387,789

  • 6c · Rental income or loss

    real property $0 · personal property $0

  • 7a · Gross sales of assets other than inventory

    securities $142,380,115

  • 7b · Less cost or other basis and sales expenses

    securities $138,723,709

  • 7c · Gain or loss

    securities $3,656,406 · other assets $0

  • 7d · Net gain or loss

    total $3,656,406 · related or exempt $0 · unrelated business $0 · excluded $3,656,406

  • 8c · Net income from fundraising events

    total $0

  • 11a · Other revenue: MISCELLANEOUS INCOME

    total $932,353 · related or exempt $0 · unrelated business $0 · excluded $932,353

  • 11d · All other revenue

    total $0 · related or exempt $0 · unrelated business $0 · excluded $0

  • 11e · Other revenue, total

    $932,353

Functional expenses

Part IX, the statement of functional expenses.

  • 3 · Grants to foreign organizations and individuals

    total $359,938 · program services $359,938

  • 4 · Benefits paid to or for members

    total $0 · program services $0

  • 5 · Compensation of officers, directors and key employees

    total $4,529,643 · program services $3,106,359 · management and general $1,077,293 · fundraising $345,991

  • 7 · Other salaries and wages

    total $10,141,255 · program services $7,961,031 · management and general $1,635,853 · fundraising $544,371

  • 8 · Pension plan contributions

    total $942,313 · program services $744,950 · management and general $146,067 · fundraising $51,296

  • 9 · Other employee benefits

    total $1,606,557 · program services $1,260,908 · management and general $264,453 · fundraising $81,196

  • 10 · Payroll taxes

    total $742,235 · program services $564,161 · management and general $134,862 · fundraising $43,212

  • 11b · Fees: legal

    total $822,060 · program services $722,908 · management and general $99,152 · fundraising $0

  • 11c · Fees: accounting

    total $142,596 · program services $43,000 · management and general $99,596 · fundraising $0

  • 11f · Fees: investment management

    total $281,815 · program services $0 · management and general $281,815 · fundraising $0

  • 11g · Fees: other

    total $5,644,699 · program services $5,161,190 · management and general $407,709 · fundraising $75,800

  • 13 · Office expenses

    total $202,203 · program services $17,307 · management and general $183,058 · fundraising $1,838

  • 14 · Information technology

    total $1,082,116 · program services $439,587 · management and general $605,447 · fundraising $37,082

  • 16 · Occupancy

    total $1,178,518 · program services $858,816 · management and general $242,283 · fundraising $77,419

  • 17 · Travel

    total $904,955 · program services $607,018 · management and general $237,153 · fundraising $60,784

  • 19 · Conferences, conventions and meetings

    total $105,276 · program services $92,770 · management and general $12,506 · fundraising $0

  • 22 · Depreciation, depletion and amortization

    total $263,420 · program services $193,961 · management and general $51,513 · fundraising $17,946

  • 23 · Insurance

    total $215,254 · program services $60,704 · management and general $154,550 · fundraising $0

  • 24a · Other expenses: R&D PROJECT EXPENSES

    total $32,128,355 · program services $32,128,355 · fundraising $0

  • 24b · Other expenses: DUES AND SUBSCRIPTIONS

    total $215,575 · program services $94,781 · management and general $100,031 · fundraising $20,763

  • 24e · All other expenses

    total $0 · program services $0 · management and general $0 · fundraising $0

Balance sheet

Part X, book values.

  • 1 · Cash, non-interest-bearing

    beginning of year $5,606,240 · end of year $0

  • 2 · Savings and temporary cash investments

    beginning of year $138,316,993 · end of year $34,377,400

  • 3 · Pledges and grants receivable

    beginning of year $1,821,719 · end of year $6,609,856

  • 4 · Accounts receivable

    beginning of year $1,102,554 · end of year $1,081,288

  • 5 · Loans and receivables from officers and key people

    beginning of year $0 · end of year $0

  • 6 · Loans and receivables from disqualified persons

    beginning of year $0 · end of year $0

  • 9 · Prepaid expenses and deferred charges

    beginning of year $1,426,170 · end of year $1,196,922

  • 10a · Land, buildings and equipment: cost or other basis

    $6,538,126

  • 10b · Land, buildings and equipment: accumulated depreciation

    $5,217,651

  • 10c · Land, buildings and equipment, net

    beginning of year $1,535,911 · end of year $1,320,475

  • 11 · Investments: publicly traded securities

    beginning of year $31,709,868 · end of year $80,443,114

  • 12 · Investments: other securities

    beginning of year $0 · end of year $64,373,689

  • 13 · Investments: program-related

    beginning of year $0

  • 15 · Other assets

    beginning of year $15,800,086 · end of year $14,913,684

  • 17 · Accounts payable and accrued expenses

    beginning of year $8,012,001 · end of year $8,739,913

  • 19 · Deferred revenue

    beginning of year $1,205,080 · end of year $2,621,045

  • 22 · Loans and payables to officers and key people

    beginning of year $0 · end of year $0

  • 25 · Other liabilities

    beginning of year $16,402,910 · end of year $16,645,641

  • 27 · Net assets without donor restrictions

    beginning of year $171,699,550 · end of year $176,309,829

Mission and programs · 2024

Mission

TB ALLIANCE IS A NOT-FOR-PROFIT ORGANIZATION DEDICATED TO THE DISCOVERY, DEVELOPMENT AND DELIVERY OF BETTER, FASTER-ACTING AND AFFORDABLE TUBERCULOSIS DRUGS THAT ARE AVAILABLE TO THOSE WHO NEED THEM.

Activities or mission (Part I)

TO ACCELERATE THE DISCOVERY & DEVELOPMENT OF NEW DRUGS TO FACILITATE THE CONTROL OF TUBERCULOSIS THROUGHOUT THE WORLD AND THE ACCESSIBILITY OF THESE DRUGS TO THE GLOBAL COMMUNITY.

  • RESEARCH AND DEVELOPMENT - TB ALLIANCE IS A NOT-FOR-PROFIT PRODUCT DEVELOPMENT PARTNERSHIP (PDP), UNIQUELY POSITIONED TO LEVERAGE A GLOBAL NETWORK OF PUBLIC AND PRIVATE PARTNERS TO MOST EFFICIENTLY ADVANCE TB DRUG DEVELOPMENT. A PDP BUILDS PARTNERSHIPS BETWEEN THE PUBLIC, PRIVATE, ACADEMIC, AND PHILANTHROPIC SECTORS TO DRIVE THE DEVELOPMENT OF NEW PRODUCTS FOR UNDERSERVED MARKETS. PDPS RETAIN DIRECT MANAGEMENT OVERSIGHT OF THEIR PROJECTS, THOUGH MUCH OF THE LABORATORY AND CLINICAL WORK IS DONE THROUGH EXTERNAL RESEARCH FACILITIES AND CONTRACTORS. WE COMBINE THE RESEARCH AND DEVELOPMENT EXPERTISE OF OUR STAFF WITH THE SKILLS AND RESOURCES OF OUR PARTNERS TO HARNESS THE MOST PROMISING SCIENCE WHEREVER IT MAY EXIST AROUND THE WORLD. THIS MODEL MINIMIZES COSTS, INCLUDING OVERHEAD AND INVESTMENTS IN INFRASTRUCTURE, WHILE OPTIMIZING SCIENTIFIC CAPABILITY TO SPEED NEW TB DRUG DEVELOPMENT. OUR BUSINESS MODEL AND DIVERSE PARTNERSHIPS ALLOW TB ALLIANCE TO LEVERAGE ADDITIONAL PARTNER SERVICES FOR EVERY DOLLAR INVESTED IN ITS PROGRAMS. NC-009 - NC-009 IS A PAN-PHASE 2 CLINICAL TRIAL INCORPORATING ELEMENTS OF PHASE 2A, B, AND C TO EVALUATE THE SAFETY AND EFFICACY OF A COMBINATION OF A NEW EXPERIMENTAL COMPOUND, TBAJ-876, WITH PRETOMANID AND LINEZOLID, COMPONENTS OF TB ALLIANCE'S BPAL REGIMEN. THIS REGIMEN HAS THE POTENTIAL TO SHORTEN AND IMPROVE TREATMENT FOR BOTH DRUG-SENSITIVE AND DRUG-RESISTANT FORMS OF TB. RESULTS FROM PRECLINICAL AND PHASE 1 STUDIES WERE PRESENTED AT THE 2023 UNION CONFERENCE ON LUNG HEALTH AND SHOWED THAT THE NEW COMPOUND, TBAJ-876, WHEN COMPARED WITH BEDAQUILINE (A TB MEDICINE IN THE SAME DRUG CLASS), ELIMINATED TB BACTERIA FASTER AND HAD A POTENTIALLY SAFER PROFILE. NC-009 WILL TEST DIFFERENT DOSES OF TBAJ-876 IN COMBINATION WITH PRETOMANID AND LINEZOLID AGAINST THE CURRENT STANDARD OF CARE FOR DRUG-SENSITIVE TB - ISONIAZID, RIFAMPICIN, PYRAZINAMIDE, AND ETHEMBUTOL (HRZE). ANOTHER ARM OF THE TRIAL WILL ALSO TEST PRETOMANID AND LINEZOLID IN COMBINATION WITH BEDAQUILINE (BPAL), A REGIMEN NOW RECOMMENDED BY THE WORLD HEALTH ORGANIZATION TO TREAT SOME FORMS OF DR-TB, AGAINST DRUG-SENSISTIVE TB. THE STUDY ENROLLED APPRXIMATELY 300 PARTICIPANTS WITH DRUG-SENSITIVE TB AT 21 CLINICAL TRIAL SITES IN FIVE COUNTRIES: GEORGIA, PHILIPPINES, SOUTH AFRICA, TANZANIA, AND UGANDA. Q203 - TELACEBEC (Q203) IS A FIRST-IN-CLASS DRUG CANDIDATE AGAINST MYCOBACTERIUM TUBERCULOSIS INFECTION. Q203 TARGETS CYTOCHROME BC1 COMPLEX AND SHOWS POTENT ACTIVITY AGAINST MULTIDRUG-RESISTANT TUBERCULOSIS (MDR-TB). Q203 HAS ALSO BEEN FOUND EFFECTIVE AGAINST BURULI ULCER (MYCOBACTERIUM ULCERANS), A CHRONIC, NECROTIZING DISEASE THAT AFFECTS SKIN AND SOMETIMES BONE AND CAN LEAD TO PERMANENT DEFORMITY AND LONG-TERM DISABILITY, AND LEPROSY (MYCOBACTERIUM LEPRAE). IN 2023, TB ALLIANCE IN-LICENSED Q203 FROM QURIENT, A CLINICAL-STAGE BIOTECHNOLOGY COMPANY BASED IN SOUTH KOREA. IN JULY 2024, A PHASE 2 PROOF-OF-CONCEPT STUDY WAS INITIATED TO EXPLORE THE USE OF TELACEBEC (Q203) TO TREAT BURULI ULCER. IF SUCCESSFUL, A SINGLE DRUG COULD CUT TREATMENT DURATION BY MORE THAN HALF. IN PARTNERSHIP WITH TB ALLIANCE AND WITH SUPPORT FROM QURIENT CO. LTD, PROFESSOR DANIEL O'BRIEN - A PROMINENT CLINICIAN-RESEARCHER AND EXPERT IN BURULI ULCER - IS LEADING THE STUDY AT BARWON HEALTH AND THE ROYAL MELBOURNE HOSPITAL IN AUSTRALIA. THE TRIAL WILL ENROLL APPROXIMATELY 40 ADULT PATIENTS WITH BURULI ULCER WHO WILL RECEIVE 28 DAYS OF TELACEBEC (300MG) ONCE DAILY, FOLLOWED BY A YEAR OF OBSERVATION. PRELIMINARY RESULTS ARE EXPECTED IN 2025. TBAJ-587 - THIS NEXT-GENERATION DIARYLQUINOLINE PROJECT HAS SHOWN POTENTIAL TO MAINTAIN BEDAQUILINE'S IMPRESSIVE ANTI-TB ACTIVITIES WHILE RETAINING ADDITIONAL IMPROVED PROPERTIES. TBAJ-587 IS BEING STUDIED THROUGH THE INNOVATIVE HEALTH INITIATIVE'S ERA4TB PROJECT AND, IN 2024, TBAJ-587 COMPLETED A PHASE I TRIAL DEMONSTRATING POSITIVE RESULTS. RESULTS PUBLICATIONS ARE UNDERWAY. SUTEZOLID - SUTEZOLID IS A PROMISING CLINICAL-STAGE TB DRUG CANDIDATE FROM THE OXAZOLIDINONE CLASS. TB ALLIANCE HAS IMPLEMENTED AN OPEN DEVELOPMENT APPROACH TO ADVANCE THE PHASE 2 TB DRUG CANDIDATE, SUTEZOLID, WHICH COULD BE A COMPONENT OF A NEXT-GENERATION TB REGIMEN. TB ALLIANCE HAS MADE SUTEZOLID AVAILABLE FOR STUDY BY ALL RESEARCHERS WHO COMMIT TO MAKING THEIR RESULTS AVAILABLE TO THE BROADER TB RESEARCH COMMUNITY. THIS NOVEL APPROACH HAS CONTRIBUTED TO THREE CLINICAL TRIALS THAT BEGAN IN 2023. PEERLINC - IN 2024, TB ALLIANCE LAUNCHED A NEW PEER-TO-PEER LEARNING FOR INNOVATIVE CURES (PEERLINC) KNOWLEDGE HUB BASED IN MANILA, WITH FUNDING FROM THE AUSTRALIAN GOVERNMENT THROUGH THE PARTNERSHIPS FOR A HEALTHY REGION INITIATIVE. PEERLINC, OPERATING IN PARTNERSHIP BETWEEN TB ALLIANCE AND THE TROPICAL DISEASE FOUNDATION, INC. (TDF), AND IN CLOSE COLLABORATION WITH THE DEPARTMENT OF HEALTH (DOH), PHILIPPINES, WILL HELP COUNTRIES IMPLEMENT BEST PRACTICES IN THE TREATMENT OF DRUG-RESISTANT TUBERCULOSIS (DR-TB) TO HELP SPEED THE WORLDWIDE PROGRAMMATIC IMPLEMENTATION OF INNOVATIVE, MORE EFFECTIVE TREATMENTS FOR THE DISEASE, STARTING WITH THE WORLD HEALTH ORGANIZATION (WHO)-RECOMMENDED SIX-MONTH, ALL-ORAL BPAL/M REGIMENS, COMPOSED OF THE ANTIBIOTICS BEDAQUILINE (B), PRETOMANID (PA), AND LINEZOLID (L), WITH OR WITHOUT MOXIFLOXACIN (M). PEERLINC WILL PROVIDE PRACTICAL TRAINING AND TECHNICAL ASSISTANCE TO COUNTRIES TO SUPPORT THIS OBJECTIVE, VIA EXPERTS FROM THE PHILIPPINES AND THE DEPARTMENT OF HEALTH, INCLUDING LUNG CENTER OF THE PHILIPPINES AND THE NATIONAL TB REFERENCE LABORATORY (NTRL). THE PHILIPPINES HAS SUCCESSFULLY AND RAPIDLY DEPLOYED NEW TREATMENTS THROUGH PARTICIPATION IN TB ALLIANCE'S LEVERAGING INNOVATION FOR FASTER TB TREATMENT (LIFT-TB) INITIATIVE. IN 2024 ALONE, THE PEERLINC KNOWLEDGE HUB COMPLETED TRAININGS WITH LEADERS, EXPERTS, AND STAFF FROM NATIONAL TB PROGRAMS IN SEVEN COUNTRIES: PERU, DRC, NIGERIA, BRAZIL, CAMBODIA, TANZANIA, RWANDA. LIFT-TB (LEVERAGING INNOVATION FOR FASTER TREATMENT OF TB) - THIS ACCESS PROGRAM, LAUNCHED IN 2020, SEEKS TO INCREASE TREATMENT COMPLETION RATES FOR DRUG-RESISTANT TB THROUGH ADOPTION AND SCALE UP OF NEW REGIMENS, BEGINNING WITH BPAL. IT FOCUSES ON SEVEN HIGH-BURDEN SOUTHEAST AND CENTRAL ASIAN COUNTRIES THAT SHOULDER APPROXIMATELY 1 IN 5 OF THE GLOBAL TB CASES. AS OF 2024, MORE THAN 100 COUNTRIES HAVE PROCURED THE SIX-MONTH, ALL-ORAL BPAL REGIMEN TO TREAT MORE THAN 180,000 PEOPLE WITH DRUG-RESISTANT TB. FAST TRACK THE CURE - IN SUPPORT OF THE WORLD HEALTH ORGANIZATION'S CALL TO ACTION TO ACCELERATE ACCESS TO SHORTER DR-TB CURES FOR ALL, THE FAST TRACK THE CURE MOVEMENT BRINGS COMMUNITIES AROUND THE WORLD TOGETHER TO RAISE AWARENESS AND FACILITATE ACCESS TO NEW DR-TB TREATMENTS, WHILE RAMPING UP ADVOCACY TO CONVINCE WORLD LEADERS THAT SIX-MONTH DR-TB CURES MUST BE WIDELY ADOPTED AND AVAILABLE TO ALL WHO NEED THEM. FAST TRACK THE CURE IS ALSO COLLABORATING CLOSELY WITH STOP TB TO ENSURE STRATEGIC ALIGNMENT AND PARTNERSHIP AND WITH THE CHALLENGE FACILITY FOR CIVIL SOCIETY MOVEMENT, BY ALIGNING WITH THEIR COMMUNITY ENGAGEMENT, CAPACITY BUILDING, AND DEMAND CREATION PILLARS AND FOCUS. SLASH-TB - TB ALLIANCE AND THE SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE HAVE DEVELOPED SLASH-TB (SAVINGS FROM LEVERAGING & ADOPTING SHORTER & HIGHLY EGGECTIVE TB TREATMENTS), A MODEL TO ESTIMATE COST SAVINGS FOR HEALTH SERVICE SYSTEMS, PATIENTS, FAMILIES, AND/OR CAREGIVERS WHEN USING THE BPAL/M REGIMENS AS COMPARED TO STANDARD DRUG-RESISTANT TB TREATMENTS.

    Expenses $47,923,018

  • PUBLIC AFFAIRS AND POLICY - TB ALLIANCE MAINTAINS CRITICAL ALLIANCES WITH PUBLIC AND PRIVATE ORGANIZATIONS TO RAISE AWARENESS ABOUT TUBERCULOSIS ("TB") AND ADVOCATE FOR PUBLIC AND PRIVATE INVOLVEMENT IN RESEARCH FOR THE PUBLIC GOOD. SPECIFICALLY, TB ALLIANCE NEGOTIATES TERMS THAT SUPPORT THE DEVELOPMENT AND ACCESS OF NEW AFFORDABLE ANTI-TB DRUGS EQUITABLY FOR THOSE AREAS MOST IN NEED WHILE ENCOURAGING THE PRIVATE SECTOR ON THE DEVELOPMENT OF THESE MEDICINES. TB ALLIANCE CONTINUES TO PURSUE AN EXPLICIT COMMITMENT TO OUR "AAA MANDATE" - THAT ALL NEW PRODUCTS WILL BE ADOPTED, AVAILABLE AND AFFORDABLE TO THOSE WITH TB.

    Expenses $5,642,489 · Grants $359,938

  • BUSINESS DEVELOPMENT - TB ALLIANCE NEGOTIATES, IMPLEMENTS AND MANAGES AGREEMENTS WITH PUBLIC AND PRIVATE ORGANIZATIONS WORLDWIDE AND DOES SO BY ADHERING TO SOUND BUSINESS PRACTICES WHILE ENSURING THE PUBLIC GOOD. SPECIFICALLY, TB ALLIANCE NEGOTIATES TERMS THAT SUPPORT THE DEVELOPMENT AND ACCESS OF NEW AFFORDABLE ANTI-TB DRUGS EQUITABLY TO THOSE AREAS MOST IN NEED WHILE ENCOURAGING THE PRIVATE SECTOR TO HELP DEVELOP NEW MEDICINES FOR TB INDICATIONS.

    Expenses $852,237

As filed on the 2024 return.

Listed in Part VII

  • Ariel Pablos-Mendez

    VICE-CHAIR

    Total calculated
    $0
    Hours/week
    3
  • David Norton

    CHAIR

    Total calculated
    $0
    Hours/week
    3
  • Dr Melvin Spigelman

    PRESIDENT/CEO

    Total calculated
    $1,052,936
    From this org
    $939,703
    From related orgs
    $0
    Other
    $113,233
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $664,638
    Bonus
    $275,065
    Other
    $0
    Deferred
    $69,000
    Nontaxable benefits
    $44,233
    Filer's total
    $1,052,936
  • Akshay Vaishnaw

    DIRECTOR (AS OF 12/01/24)

    Total calculated
    $0
    Hours/week
    3
  • Ann Taylor

    DIRECTOR (AS OF 09/01/24)

    Total calculated
    $0
    Hours/week
    3
  • Eric Goosby

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • Kim Schwartz

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • Mitchell Warren

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • Rasha Hibri

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • Ratan Watal

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • Srishti Gupta

    DIRECTOR (AS OF 12/01/24)

    Total calculated
    $0
    Hours/week
    3
  • Sundar Kodiyalam

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • Angela Vanderploeg

    TREASURER/CFO

    Total calculated
    $526,225
    From this org
    $421,854
    From related orgs
    $0
    Other
    $104,371
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $334,028
    Bonus
    $87,826
    Other
    $0
    Deferred
    $42,395
    Nontaxable benefits
    $61,976
    Filer's total
    $526,225
  • Colleen Pero

    SECRETARY/CAO

    Total calculated
    $541,142
    From this org
    $470,044
    From related orgs
    $0
    Other
    $71,098
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $375,473
    Bonus
    $94,571
    Other
    $0
    Deferred
    $46,106
    Nontaxable benefits
    $24,992
    Filer's total
    $541,142
  • Dr Eugene Sun

    SR. VP, RESEARCH & DEVELOPMENT

    Total calculated
    $674,243
    From this org
    $580,925
    From related orgs
    $0
    Other
    $93,318
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $461,947
    Bonus
    $118,978
    Other
    $0
    Deferred
    $54,642
    Nontaxable benefits
    $38,676
    Filer's total
    $674,243
  • Dr Nader Fotouhi

    SR. VP, CHIEF SCIENTIFIC OFFICER

    Total calculated
    $683,612
    From this org
    $565,207
    From related orgs
    $0
    Other
    $118,405
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $448,750
    Bonus
    $116,457
    Other
    $0
    Deferred
    $56,266
    Nontaxable benefits
    $62,139
    Filer's total
    $683,612
  • Maria Beumont

    VP, CHIEF MEDICAL OFFICER

    Total calculated
    $584,002
    From this org
    $497,709
    From related orgs
    $0
    Other
    $86,293
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $412,534
    Bonus
    $85,175
    Other
    $0
    Deferred
    $46,000
    Nontaxable benefits
    $40,293
    Filer's total
    $584,002
  • Pietro O Turilli

    SR. VP, EXTERNAL AFFAIRS

    Total calculated
    $467,483
    From this org
    $369,474
    From related orgs
    $0
    Other
    $98,009
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $293,361
    Bonus
    $76,113
    Other
    $0
    Deferred
    $36,741
    Nontaxable benefits
    $61,268
    Filer's total
    $467,483
  • Kathleen Schostack

    SR. VP, PROGRAM & ALLIANCE MANAGEMENT

    Total calculated
    $518,559
    From this org
    $432,300
    From related orgs
    $0
    Other
    $86,259
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $343,593
    Bonus
    $88,707
    Other
    $0
    Deferred
    $42,820
    Nontaxable benefits
    $43,439
    Filer's total
    $518,559
  • Rajneesh Taneja

    VP, PHARMACEUTICAL PRODUCT DEVELOPMENT

    Total calculated
    $451,668
    From this org
    $370,728
    From related orgs
    $0
    Other
    $80,940
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $306,440
    Bonus
    $64,288
    Other
    $0
    Deferred
    $36,902
    Nontaxable benefits
    $44,038
    Filer's total
    $451,668
  • Robert Lorette

    SR. VP, BUSINESS DEVELOPMENT

    Total calculated
    $536,240
    From this org
    $448,954
    From related orgs
    $0
    Other
    $87,286
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $357,997
    Bonus
    $90,957
    Other
    $0
    Deferred
    $43,907
    Nontaxable benefits
    $43,379
    Filer's total
    $536,240
  • Salah Foraida

    SR. DIRECTOR, MEDICAL AFFAIRS

    Total calculated
    $482,498
    From this org
    $430,090
    From related orgs
    $0
    Other
    $52,408
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $373,254
    Bonus
    $56,836
    Other
    $0
    Deferred
    $42,937
    Nontaxable benefits
    $9,471
    Filer's total
    $482,498
  • Sandeep Juneja

    SR. VP, MARKET ACCESS

    Total calculated
    $521,229
    From this org
    $417,509
    From related orgs
    $0
    Other
    $103,720
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $330,811
    Bonus
    $86,698
    Other
    $0
    Deferred
    $41,851
    Nontaxable benefits
    $61,869
    Filer's total
    $521,229

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

  • 3 · Compensation committee
  • 3 · Independent compensation consultant
  • 3 · Form 990 of other organizations
  • 3 · Compensation survey or study
  • 3 · Approval by the board or compensation committee
  • 7 · Other non-fixed payments

Answered no

  • 4a · Severance or change-of-control payment
  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 8 · Paid under the initial-contract exception

The filer's explanations (Part III)

Schedule J, Part I, Line 7 Non-fixed payments
VARIABLE COMPENSATION IS PAID TO STAFF MEMBERS BASED ON ANNUAL PERFORMANCE. REFER TO SCHEUDLE O RESPONSE TO FORM 990, PART VI, SECTION B, LINES 15 A and 15B FOR FURTHER DETAILS.

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

No itemized grants to organizations on this return.

Provenance

Return type
form_990
Tax year
2024
Filed
24 October 2025
IRS schema version
2024v5.1
Source object
202542969349302084

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.